Insider · CIK 0002051489
Keli Walbert
director
Files at APLS (Apellis Pharmaceuticals, Inc.), SPRB (SPRUCE BIOSCIENCES, INC.), COAG (Hemab Therapeutics Holdings, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | COAG Hemab Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | 17 d ago |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 17,051 | Jan 5, 2026 |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Dec 11, 2025 | SPRB SPRUCE BIOSCIENCES, INC. | AGrant or award Stock Option (Right to Buy)derivative | +3,400 | $0.00 | $0 | 3,400 | Dec 15, 2025 |
| Jan 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +9,090 | $0.00 | $0 | 9,090 | Jan 10, 2025 |
| Jan 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,388 | $33.00 | $508k | 15,388 | Jan 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.